Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial (Q44963629)
Jump to navigation
Jump to search
scientific article published on 4 September 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial |
scientific article published on 4 September 2013 |
Statements
1 reference
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial (English)
1 reference
Gregory S Thomas
1 reference
Shariq Ali
1 reference
Wai Chin
1 reference
JoAnn D Flaim
1 reference
Michael Davidson
1 reference
4 September 2013
1 reference
1 reference
62
1 reference
23
1 reference
2178-2184
1 reference
Identifiers
1 reference
1 reference